Chocamine Plus (Theobroma cacao extract)

Chocamine Plus is a proprietary Theobroma cacao extract standardized to deliver theobromine, phenylethylamine (PEA), caffeine, and polyphenols in ratios mirroring natural cacao. It works primarily through adenosine receptor antagonism via theobromine and PEA-mediated catecholamine release to support sustained energy and cognitive function.

Origin & History

Chocamine Plus is a branded, proprietary extract derived from Theobroma cacao (cacao) beans native to Central and South America. It is produced as a low-fat cocoa powder extract, standardized to ≥12% theobromine and ≥0.5% caffeine via HPLC, with additional ingredients including 75-85% cocoa extract, ≥2% vanilla flavor, and tapioca starch.

Historical & Cultural Context

Theobroma cacao, the source of Chocamine Plus, has been valued for centuries in Central and South American indigenous traditions as both food and medicine. However, no specific historical medicinal uses are documented for the branded extract itself.

Health Benefits

• May improve focus, concentration, and short-term memory (evidence quality: limited - claims referenced but no study details provided)
• Provides smoother, longer-lasting energy compared to caffeine through theobromine content (evidence quality: theoretical based on compound properties)
• Supports vasodilation for improved oxygen and nutrient transport (evidence quality: mechanistic understanding, no direct clinical evidence)
• Delivers antioxidant effects from flavonoids and polyphenols (evidence quality: general cocoa research, not Chocamine-specific)
• May promote cardiovascular support (evidence quality: general cocoa extract studies show benefits at >100 mg/day flavanols, but not tied to Chocamine)

How It Works

Theobromine, the dominant methylxanthine in Chocamine Plus, acts as a mild adenosine A1 and A2A receptor antagonist, reducing inhibitory signaling to produce smoother, longer-duration stimulation compared to caffeine due to its slower metabolism and longer half-life of approximately 7–12 hours. Phenylethylamine (PEA) promotes release of dopamine and norepinephrine in the synaptic cleft and inhibits their reuptake, contributing to transient mood elevation and heightened alertness. Polyphenolic flavanols such as epicatechin may additionally support cerebral blood flow by upregulating endothelial nitric oxide synthase (eNOS), enhancing oxygen and nutrient delivery to neural tissue.

Scientific Research

Despite commercial claims of clinical studies showing improved focus, concentration, and short-term memory, the research dossier reveals no specific human clinical trials, RCTs, or meta-analyses directly on Chocamine Plus. General cocoa research (PMC8814059) notes cardiovascular benefits from flavan-3-ols at doses >100 mg/day, but these studies are not specific to the Chocamine branded extract.

Clinical Summary

Robust human clinical trials specifically on the Chocamine Plus branded extract are currently lacking in the published literature, making direct efficacy claims difficult to substantiate at the ingredient level. Research on Theobroma cacao extracts and isolated theobromine suggests cognitive benefits, including one small crossover study (n=24) showing improved sustained attention and reduced mental fatigue with theobromine doses of 250–700 mg. PEA has demonstrated rapid mood-elevating effects in small human trials, though its oral bioavailability is limited due to rapid MAO-B metabolism, which the full cacao matrix may partially offset. Overall, the evidence base is preliminary and largely mechanistic or derived from component-level research rather than Chocamine Plus-specific randomized controlled trials.

Nutritional Profile

Chocamine Plus is a proprietary standardized extract of Theobroma cacao (cocoa bean) optimized for its bioactive alkaloid and polyphenol content rather than macronutrient delivery. Key bioactive compounds include: Theobromine (primary alkaloid, typically 12–20% of extract by standardization, approximately 200–350mg per typical 1–1.75g serving dose), functioning as a mild xanthine stimulant and vasodilator; Caffeine (minor alkaloid, approximately 0.1–0.5% of extract, significantly lower ratio than coffee, estimated 5–20mg per serving); Phenylethylamine (PEA, trace alkaloid, approximately 0.1–0.5% concentration, rapidly metabolized in vivo limiting bioavailability unless combined with MAO-B inhibitors); Polyphenols including epicatechin and catechin flavonoids (estimated 5–15% total polyphenol content by Folin-Ciocalteu equivalent); Tyramine and tryptamine (trace biogenic amines, sub-milligram quantities per serving). Micronutrient contribution is minimal at typical extract doses: trace magnesium (estimated 2–8mg per gram of extract), trace copper, and negligible iron. Fiber, protein, and fat content are essentially absent in concentrated extract form compared to whole cacao powder. Bioavailability notes: Theobromine has high oral bioavailability (~85–90%) with slow hepatic metabolism (half-life 6–10 hours), explaining its sustained-effect profile. PEA bioavailability is inherently poor orally due to rapid MAO-A/B degradation in gut and liver. Polyphenol absorption is variable (15–30%) and dependent on gut microbiome composition.

Preparation & Dosage

Commercial products typically use 500 mg per serving of Chocamine cacao powder complex, often combined with other ingredients like GABA or caffeine. No clinically studied dosage ranges have been established specifically for Chocamine Plus. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

GABA, L-theanine, Rhodiola rosea, B-complex vitamins, Magnesium

Safety & Interactions

Chocamine Plus is generally well tolerated at typical supplemental doses, but theobromine content can cause nausea, headache, or heart palpitations at higher intakes, particularly in individuals sensitive to methylxanthines. It may potentiate the effects of other stimulants including caffeine, ephedrine, or ADHD medications, increasing cardiovascular strain and the risk of elevated heart rate or blood pressure. MAO inhibitor (MAOI) medications represent a significant contraindication due to the PEA content, which can cause hypertensive crisis when MAO-B is blocked. Pregnant or breastfeeding individuals should exercise caution, as methylxanthines cross the placenta and are excreted in breast milk, with high intake associated with adverse fetal outcomes.